12 Health Care Stocks Moving In Monday’s After-Market Session
Gainers Owlet (NYSE:OWLT) shares rose 43.8% to $0.49 during Monday’s after-market session. At the close, Owlet’s trading volume…
February PDUFA Catalysts Biotech Investors Must Know: Sanofi’s Bleeding Disorder Drug, Regeneron’s Twin Eylea Label Expansions, 3 Delayed Approvals And More
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new molecular entities for the year.
Apellis Pharmaceuticals Expects To Report About $65M Net Product Revenue From Sales Of EMPAVELI In The U.S For Year Ended Dec 31, 2022
On January 9, 2023, Apellis Pharmaceuticals, Inc. (the “Company”) posted on its website a corporate presentation, which it plans to present at the 41st Annual J.P. Morgan Health Care Conference on
What 5 Analyst Ratings Have To Say About Apellis Pharmaceuticals
Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Wells Fargo Downgrades Apellis Pharmaceuticals to Equal-Weight, Announces $58 Price Target
Wells Fargo analyst Derek Archila downgrades Apellis Pharmaceuticals (NASDAQ:APLS) from Overweight to Equal-Weight and announces $58 price target.
Foot Locker, Ross Stores, Palo Alto Networks, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 200 points. Here is the list of some big stocks recording gains in the previous session.
Why PaxMedica Shares Are Trading Higher By Over 53%? Here Are 47 Stocks Moving In Friday’s Mid-Day Session
Gainers
PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital.
12 Health Care Stocks Moving In Friday’s Intraday Session
Gainers IVERIC bio (NASDAQ:ISEE) shares increased by 26.7% to $21.84 during Friday’s regular session. As of 12:30 EST,…
Apellis Pharma Shares Jump As FDA Accepts Its Lead Product Application For Eye Disease
The FDA has accepted for review Apellis Pharmaceuticals Inc’s (NASDAQ:APLS) unsolicited major amendment to the New Drug Application (NDA) for intravitreal…
JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Lowers Price Target to $79
JP Morgan analyst Anupam Rama maintains Apellis Pharmaceuticals (NASDAQ:APLS) with a Overweight and lowers the price target from $81 to $79.